公开(公告)号：US20220259633A1

公开(公告)日：2022-08-18

申请号：US17630657

申请日：2020-08-26

Applicant: EUBIOLOGICS CO., LTD. ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Kyu LEE ,  Da Hui HA ,  Choon Geun LEE ,  Ye Ram LEE ,  Hak Suk CHUNG

IPC: C12P19/44

Abstract: Provided is a method of producing monophosphoryl lipid A (MPLA). According to the method, MPLA may be produced with high purity and high purity by using a bacterium producing MPLA.

公开(公告)号：US20240148856A1

公开(公告)日：2024-05-09

申请号：US18495475

申请日：2023-10-26

Applicant: EUBIOLOGICS CO., LTD.

Inventor： Chan Kyu LEE ,  Jonathan F. LOVELL ,  Yoon Hee WHANG ,  Woo Yeon HWANG ,  Hye Ji KIM ,  Min Chul PARK ,  Seok Kyu KIM ,  Wei-Chiao HUANG ,  Da Hui HA

IPC: A61K39/155 ,  A61P31/14 ,  C07K1/18 ,  C07K1/22 ,  C07K7/00 ,  C07K14/005 ,  C12N5/071

CPC classification number: A61K39/155 ,  A61P31/14 ,  C07K1/18 ,  C07K1/22 ,  C07K7/00 ,  C07K14/005 ,  C12N5/0682 ,  A61K2039/55555

Abstract: Provided is a vaccine composition for preventing respiratory syncytial virus (RSV) infection, which is in the form of a liposome formulation including a RSV antigen, monophosphoryl lipid A (MLA), and/or a cobalt-porphyrin-phospholipid (CoPoP) conjugate. The vaccine composition exhibits excellent vaccine efficacy from a RSV antigen with enhanced immunogenicity and a combination of immune adjuvants for enhancing immune activity and antigen presentation.

公开(公告)号：US20240033346A1

公开(公告)日：2024-02-01

申请号：US18023580

申请日：2021-09-02

Applicant: EUBIOLOGICS CO., LTD. ,  POP BIOTECHNOLOGIES, INC.

Inventor： Chan Kyu LEE ,  Jonathan F. LOVELL ,  Jee Sun YUN ,  Seok Kyu KIM ,  Byung Man LEE ,  Da Hui HA ,  Jeong Yoon LEE ,  Choon Geun LEE ,  Ye Ram LEE ,  Wei-Chiao HUANG ,  Jemin HAN

IPC: A61K39/25 ,  A61P31/20

CPC classification number: A61K39/25 ,  A61P31/20 ,  A61K2039/55572

Abstract: Provided are a vaccine composition for Varicella Zoster virus (VZV) including a glycoprotein E (gE) antigen of VZV and monophosphoryl lipid A (MLA), and a method of using the same. The vaccine composition according to an aspect of the invention may significantly improve a production yield by including the gE antigen having an optimized signal peptide sequence, may enhance immunogenicity by including MLA, and may further enhance the immunogenicity enhanced by MLA by further adding saponin such as QS-21, and may be prepared in a form of CoPoP liposomes so that vaccine antigens may be presented on the surface of the liposomes for better absorption by antigen-presenting cells, and vaccine efficacy may be maximized by inclusion of the vaccine antigens and immune adjuvants in a formulation. Therefore, the vaccine composition may be useful as an alternative to current vaccines in the art for prevention or treatment of VZV infection.